BioMark Diagnostics (TSE:BUX) has released an update.
BioMark Diagnostics Inc. has received significant non-dilutive funding to pursue the development of a novel cancer treatment targeting Glioblastoma, an aggressive brain tumor with limited effective therapies. The research, led by Dr. Donald Miller, focuses on an injectable drug delivery platform designed to enhance radiation and chemotherapy responses, with upcoming animal trials marking a critical step toward potential clinical application. The project’s innovation and potential have been recognized through competitive grants from Research Manitoba and Mitacs, highlighting BioMark’s commitment to advancing cancer treatment.
For further insights into TSE:BUX stock, check out TipRanks’ Stock Analysis page.
